Skip to main content

and
  1. No Access

    Article

    Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer

    Polymorphisms of genes involved in estrogen synthesis have been linked to breast cancer risk, prognosis, and treatment response. We investigated the prognostic impact of a deletion spanning the entire UGT2B17 gen...

    Harriet Johansson, Valentina Aristarco, Sara Gandini in The Pharmacogenomics Journal (2020)

  2. Article

    Open Access

    Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

    Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 ...

    Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni in npj Breast Cancer (2021)

  3. Article

    Open Access

    Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation

    In a 3-arm presurgical trial, four-six weeks exemestane 25 mg three times/week (TIW) was non-inferior to 25 mg/day (QD) in suppressing circulating estradiol in postmenopausal women with ER-positive breast canc...

    Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini in npj Breast Cancer (2024)